90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + Placebo
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Bronchial Asthma
Conditions
Bronchial Asthma
Trial Timeline
Dec 1, 2015 โ Nov 1, 2016
NCT ID
NCT02624505About 90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + Placebo
90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + Placebo is a phase 3 stage product being developed by Cipla for Bronchial Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT02624505. Target conditions include Bronchial Asthma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02624505 | Phase 3 | Completed |
Competing Products
20 competing products in Bronchial Asthma
Other Products from Cipla
Generic HAART Triomune : d4T, 3TC, NVP + Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABVApproved
85
Insulin Lispro-aabc + Insulin GlargineApproved
85
CBT124 + EU-sourced Avastinยฎ + Carboplatin + PaclitaxelPhase 3
77
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 + Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 + PlaceboPhase 3
77
Budesonide 80 ฮผg and Formoterol Fumarate Dihydrate 4.5 ฮผg + Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol + PlaceboPhase 3
77